AAV serotype 2 vectors preferentially integrate into active genes in mice

Nature Genetics

Volumn 34, Issue 3, 2003, Pages 297-302

  Nakai, Hiroyuki ^a   Montini, Eugenio ^b,d   Fuess, Sally ^a   Storm, Theresa A ^a   Grompe, Markus ^b,c   Kay, Mark A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME DELETION; CHROMOSOME INTEGRATION; CONTROLLED STUDY; DNA INTEGRATION; EXTRACHROMOSOMAL VECTOR GENOME; FEMALE; GENE EXPRESSION; GENE INTEGRATION; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; GENOME; LIVER; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECOMBINANT ADENO ASSOCIATED VIRUS SEROTYPE 2; RETROVIRAL INSERTIONAL MUTAGENESIS; SOMATIC CELL; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; BASE SEQUENCE; CELL LINE; CHROMOSOME DELETION; CHROMOSOMES; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES; GENETIC VECTORS; HEPATOCYTES; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMIDS; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS INTEGRATION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 0038054338     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1179     Document Type: Article

References (29)

1. Kay, M.A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261 (2000).
2. Nakai, H. et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75, 6969-6976 (2001).
3. Miao, C.H. et al. The kinetics of rAAV integration in the liver. Nat. Genet. 19, 13-15 (1998).
4. Nakai, H., Iwaki, Y., Kay, M.A. & Couto, L.B. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J. Virol. 73, 5438-5447 (1999).
5. Chen, S.J., Tazelaar, J., Moscioni, A.D. & Wilson, J.M. In vivoselection of hepatocytes transduced with adeno-associated viral vectors. Mol. Ther. 1, 414-422 (2000).
6. Li, Z. et al. Murine leukemia induced by retroviral gene marking. Science 296, 497 (2002).
7. Marshall, E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science 298, 34-35 (2002).
8. Marshall, E. Gene therapy. Second child in French trial is found to have leukemia. Science 299, 320 (2003).
9. Rutledge, E.A. & Russell, D.W. Adeno-associated virus vector integration junctions. J. Virol. 71, 8429-8436 (1997).
10. Yang, C.C. et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J. Virol. 71, 9231-9247 (1997).
11. Miller, D.G., Rutledge, E.A. & Russell, D.W. Chromosomal effects of adeno-associated virus vector integration. Nat. Genet. 30, 147-148 (2002).
12. Waterston, R.H. et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562 (2002).
13. Grompe, M. et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 7, 2298-2307 (1993).
14. Overturf, K. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 12, 266-273 (1996).
15. Miki, R. et al. Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc. Natl. Acad. Sci. USA 98, 2199-2204 (2001).
16. Su, A.I. et al. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA 99, 4465-4470 (2002).
17. Vijaya, S., Steffen, D.L. & Robinson, H.L. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60, 683-692 (1986).
18. Sandmeyer, S.B., Hansen, L.J. & Chalker, D.L. Integration specificity of retrotransposons and retroviruses. Annu. Rev. Genet. 24, 491-518 (1990).
19. Scherdin, U., Rhodes, K. & Breindl, M. Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 64, 907-912 (1990).
20. Chalker, D.L. & Sandmeyer, S.B. Ty3 integrates within the region of RNA polymerase III transcription initiation. Genes Dev. 6, 117-128 (1992).
21. Pryciak, P.M. & Varmus, H.E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell 69, 769-780 (1992).
22. Muller, H.P. & Varmus, H.E. DNA bending creates favored sites for retroviral integration: an explanation for preferred insertion sites in nucleosomes. EMBO J. 13, 4704-4714 (1994).
23. Pruss, D., Bushman, F.D. & Wolffe, A.P. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. Sci. USA 91, 5913-5917 (1994).
24. Leclercq, I. et al. Host sequences flanking the human T-cell leukemia virus type 1 provirus in vivo. J. Virol. 74, 2305-2312 (2000).
25. Schroder, A.R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
26. Nakai, H, et al. Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol. Ther. 7, 101-111 (2003).
27. Diehn, M. et al. SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 31, 219-223 (2003).
28. Lander, E.S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
29. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).